Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.

Vargas L, Hamasy A, Nore BF, Smith CI.

Scand J Immunol. 2013 Aug;78(2):130-9. doi: 10.1111/sji.12069. Review.

2.

TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.

Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ, Smith CI.

FEBS J. 2011 Jun;278(12):2001-10. doi: 10.1111/j.1742-4658.2011.08134.x. Epub 2011 May 18. Review.

3.

Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Ponader S, Burger JA.

J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28.

4.

BTK Signaling in B Cell Differentiation and Autoimmunity.

Corneth OB, Klein Wolterink RG, Hendriks RW.

Curr Top Microbiol Immunol. 2016;393:67-105. doi: 10.1007/82_2015_478. Review.

PMID:
26341110
5.

Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec.

Tomlinson MG, Kane LP, Su J, Kadlecek TA, Mollenauer MN, Weiss A.

Mol Cell Biol. 2004 Mar;24(6):2455-66.

6.

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E.

Cancer Treat Rev. 2017 Jul;58:41-50. doi: 10.1016/j.ctrv.2017.06.001. Epub 2017 Jun 9. Review.

PMID:
28641100
7.

Bruton's TK inhibitors: structural insights and evolution of clinical candidates.

Xing L, Huang A.

Future Med Chem. 2014 Apr;6(6):675-95. doi: 10.4155/fmc.14.24. Review.

PMID:
24895895
8.
9.

Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).

Vihinen M, Mattsson PT, Smith CI.

Front Biosci. 2000 Dec 1;5:D917-28. Review.

PMID:
11102316
10.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.

11.

Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.

Wang Y, Zhang LL, Champlin RE, Wang ML.

Clin Pharmacol Ther. 2015 May;97(5):455-68. doi: 10.1002/cpt.85. Epub 2015 Apr 3. Review.

PMID:
25669675
12.

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.

Winer ES, Ingham RR, Castillo JJ.

Expert Opin Investig Drugs. 2012 Mar;21(3):355-61. doi: 10.1517/13543784.2012.656199. Epub 2012 Feb 3. Review.

PMID:
22300471
13.

The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.

Broides A, Hadad N, Levy J, Levy R.

J Clin Immunol. 2014 Jul;34(5):555-60. doi: 10.1007/s10875-014-0046-z. Epub 2014 Apr 26.

PMID:
24771458
14.

Consequences of two naturally occurring missense mutations in the structure and function of Bruton agammaglobulinemia tyrosine kinase.

Vargas-Hernández A, López-Herrera G, Maravillas-Montero JL, Vences-Catalán F, Mogica-Martínez D, Rojo-Domínguez A, Espinosa-Rosales FJ, Santos-Argumedo L.

IUBMB Life. 2012 Apr;64(4):346-53. doi: 10.1002/iub.1009. Epub 2012 Feb 29.

15.

Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.

Alinari L, Quinion C, Blum KA.

Clin Pharmacol Ther. 2015 May;97(5):469-77. doi: 10.1002/cpt.65. Epub 2015 Jan 20. Review.

PMID:
25670208
16.

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.

Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.

Oncotarget. 2015 Jun 20;6(17):15122-36.

17.

Ibrutinib and indolent B-cell lymphomas.

Akinleye A, Furqan M, Adekunle O.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):253-60. doi: 10.1016/j.clml.2013.11.005. Epub 2013 Nov 15. Review.

PMID:
24445187
18.

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.

Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL.

Br J Haematol. 2014 Sep;166(6):849-61. doi: 10.1111/bjh.12974. Epub 2014 Jun 24.

PMID:
24957109
19.

A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.

Douhan J 3rd, Miyashiro JS, Zhou X, Cole DC, Wu PW, Collins M, Dunussi-Joannopoulos K.

Assay Drug Dev Technol. 2007 Dec;5(6):751-8. doi: 10.1089/adt.2007.9982.

PMID:
18181691
20.

X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.

Maekawa K, Yamada M, Okura Y, Sato Y, Yamada Y, Kawamura N, Ariga T.

Blood Cells Mol Dis. 2010 Apr 15;44(4):300-4. doi: 10.1016/j.bcmd.2010.01.004. Epub 2010 Feb 1.

PMID:
20122858

Supplemental Content

Support Center